A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

MLA

van der Lee, Sven J., et al. “A Nonsynonymous Mutation in PLCG2 Reduces the Risk of Alzheimer’s Disease, Dementia with Lewy Bodies and Frontotemporal Dementia, and Increases the Likelihood of Longevity.” Acta Neuropathologica, vol. 138, no. 2, Aug. 2019, pp. 237–50. EBSCOhost, https://doi.org/10.1007/s00401-019-02026-8.

APA

van der Lee, S. J., Conway, O. J., Jansen, I., Carrasquillo, M. M., Kleineidam, L., van den Akker, E., Hernández, I., van Eijk, K. R., Stringa, N., Chen, J. A., Zettergren, A., Andlauer, T. F. M., Diez-Fairen, M., Simon-Sanchez, J., Lleó, A., Zetterberg, H., Nygaard, M., Blauwendraat, C., Savage, J. E., & Mengel-From, J. (2019). A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 138(2), 237–250. https://doi.org/10.1007/s00401-019-02026-8

Chicago

van der Lee, Sven J., Olivia J. Conway, Iris Jansen, Minerva M. Carrasquillo, Luca Kleineidam, Erik van den Akker, Isabel Hernández, et al. 2019. “A Nonsynonymous Mutation in PLCG2 Reduces the Risk of Alzheimer’s Disease, Dementia with Lewy Bodies and Frontotemporal Dementia, and Increases the Likelihood of Longevity.” Acta Neuropathologica 138 (2): 237–50. doi:10.1007/s00401-019-02026-8.